Compass Therapeutics, Inc. (CMPX)
Nasdaq: CMPX · Biological Products, (No Diagnostic Substances) · Boston, MA · filing with the SEC since 2018
Who owns Compass Therapeutics, Inc.
As filed with the SECHolders of 5% or more
5
Tang Capital Management, LLC holds 9.99% of Common Stock, par value $0.0001 per share, as its SCHEDULE 13G/A filed Nov 14, 2025 says.
Directors and officers
12
report now, of 25 people on the record since 2018. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 5 named at left.
Holders of 5% or moreshare of the class, as filed
Tang Capital Management, LLC
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, par value $0.0001 per share · 9.99% in Nov 14, 2025
Orbimed Advisors LLC
SCHEDULE 13D/A · filed Aug 15, 2025 · COMMON STOCK · 11% in Apr 11, 2025
Suvretta Capital Management, LLC
SCHEDULE 13G/A · filed Aug 21, 2025 · Common Stock, $0.0001 par value per share · 5.2% in Aug 13, 2025
State Street Corporation
SCHEDULE 13G · filed Aug 7, 2026 · COMMON STOCK
Blackrock, Inc.
SCHEDULE 13G · filed Jan 21, 2026 · Common Stock · 4.6% in Jul 16, 2025
Commander Aggregator, LP
SCHEDULE 13D/A · filed Aug 18, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%
Adage Capital Management, L.P.
SCHEDULE 13G/A · filed Feb 12, 2025 · Common stock, par value $0.0001 per share · reported falling below 5%
Bvf Partners L P/il
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, $0.0001 par value per share · reported falling below 5%, from 5.1% in Oct 29, 2025
MPM BioImpact LLC
SCHEDULE 13G/A · filed Aug 12, 2025 · Common Stock, par value $0.001 per share · reported falling below 5%, from 6.2% in Feb 14, 2025
Vivo Opportunity Fund Holdings, L.P.
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 5.1% in Nov 14, 2025
Blackstone Alternative Asset Management Associates LLC
SCHEDULE 13G/A · filed Feb 13, 2026 · Common Stock, $0.0001 par value per share · reported falling below 5%
RTW Investments, LP
SCHEDULE 13G/A · filed Aug 14, 2025 · Ordinary Shares, par value GBP 0.008 per share · reported falling below 5%, from 9.9% in Aug 14, 2025
What CMPX reports owning in othersstakes of 5% or more, and other ties
Compass Therapeutics, Inc. reports no stake in another company in the record.
Insider tradesForm 4
0sales
4purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$100,000bought, in dollars
Open-market trades on Form 4 from Oct 2, 2025 to Oct 2, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 2, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window2 of 26 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Lerner Neil | Chief Accounting Officer | 0 | $0 | 0 | 3 | $0 |
| Anderman Jonathan | General Counsel | 0 | $0 | 0 | 1 | $0 |